Rhodiola

Rhodiola rosea (golden root, arctic root) is one of the better-studied adaptogenic herbs, with a clinical literature spanning stress and burnout, mental fatigue, mild-to-moderate depression, athletic performance and recovery, and cognitive function under fatigue or sleep deprivation. The herb has been used in Russian and Scandinavian folk medicine for centuries; modern research uses standardized root extracts, most commonly the SHR-5 extract that dominates the European trial literature. Active compounds include salidroside (a tyrosol glucoside) and rosavins (phenylpropanoids); the salidroside-to-rosavin ratio is one of the standardization markers but is not consistent across products.

The outcome dimensions covered most heavily are stress and fatigue symptoms (the registered traditional use in Europe), mental fatigue and cognitive function under demanding conditions, athletic performance (particularly endurance, where the literature has focused on perceived exertion and time-to-exhaustion outcomes), mild-to-moderate depression (a smaller research stream), and adaptive resilience to acute physical or psychological stressors. The mechanistic emphasis on the HPA axis and monoaminergic systems connects rhodiola to the broader adaptogen category and shapes much of the field framing.

Demographically, the European literature concentrates heavily on healthy adults under occupational stress (the dominant trial population), with secondary research streams in athletic populations, students under examination stress, and clinical anxiety/depression. Product standardization is a major practical issue: trials variously use products standardized to 3% rosavins / 1% salidroside (a common market specification), 6% rosavins, or pure salidroside, and these are not interchangeable. Trial duration is typically 4-12 weeks, similar to other herbal-supplement trials and shorter than ideal for establishing long-term effects.

Rhodiola is generally well-tolerated in clinical trials. The most-reported adverse events are mild gastrointestinal discomfort, dry mouth, dizziness, and occasional headache. Nervousness and insomnia are also reported. No established tolerable upper limit. Drug interactions are only partly characterized: one human study found modest CYP2C9 inhibition (relevant to losartan, warfarin, and phenytoin), case reports describe reactions with antidepressants (MAO inhibition is shown in vitro), and interactions with stimulants and antihypertensives remain theoretical. Use during pregnancy and breastfeeding is not recommended (EMA monograph); people with bipolar disorder or on antidepressants should consult a clinician.

This summary is informational and not medical advice. Consult a clinician before starting or changing any supplement, especially if you take prescription medications.